Overview
Clinical Meaning
NP management of substance use disorders requires expertise in medication assisted treatment (MAT), withdrawal management, and integration of psychosocial interventions.
NP management of substance use disorders requires expertise in medication-assisted treatment (MAT), withdrawal management, and integration of psychosocial interventions. Opioid Use Disorder (OUD): The three FDA-approved medications are buprenorphine, methadone, and naltrexone. Buprenorphine (partial mu-opioid agonist) is the most commonly NP-prescribed MAT: it activates mu-receptors sufficiently to prevent withdrawal and craving but has a 'ceiling effect' that limits respiratory depression risk. The X-waiver requirement was ELIMINATED in 2023 — all DEA-licensed prescribers can now prescribe buprenorphine for OUD. Buprenorphine/naloxone (Suboxone) is the standard formulation; naloxone is added to deter IV misuse (naloxone is poorly bioavailable sublingually but precipitates withdrawal if injected). Induction timing is critical: buprenorphine must not be started until the patient is in MODERATE withdrawal (COWS score ≥8-12) — starting too early precipitates withdrawal because buprenorphine displaces full agonists from receptors while providing only partial activation. Methadone (full mu-agonist) can only be dispensed through federally licensed opioid treatment programs (OTPs) — NPs cannot prescribe methadone for OUD in office-based settings. Alcohol Use Disorder (AUD): Naltrexone (opioid antagonist) 50 mg PO daily or 380 mg IM monthly reduces heavy...
